Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
Recruiting · Phase 3 · NCT05609630
Conditions: Juvenile Idiopathic Arthritis
At a glance
- Research payments reported, 2025
- $58,980
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 90
About the trial
- Sponsor
- AbbVie
- Tested
- Upadacitinib (drug), Tocilizumab (drug)
- Dates
- Started 2023-10-02; completion 2029-06
- Results posted
- Not yet
Juvenile Idiopathic Arthritis (JIA) is the most common type of arthritis that affects children. The term "idiopathic" means "of unknown origin". It is a chronic (long-lasting) disease that causes swelling, warmth, and pain of one or more small joints. Systemic JIA ia a rare and serious form of JIA. Systemic" means it may affect not only the joints but other parts of the body, including the liver, lungs and heart. sJIA is more severe and can be more challenging to diagnose and treat than other types of juvenile idiopathic arthritis. It is a lifelong disease for many patients and can continue into adulthood. This study will assess how safe and effective upadacitinib is in treating pediatric…
From ClinicalTrials.gov, last updated 2026-09-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $58,980 in research payments for this study in 2025 (15 payments).
Products named: Rinvoq
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Sangeeta Sule, M.D. Pediatrics · Washington, DC
- Thomas A. Griffin, MD Pediatrics · Charlotte, NC
- Christine Hom, MD Pediatrics · Valhalla, NY
- Grant S. Schulert, M.D. Pediatrics · Cincinnati, OH
- Daniel J. Kingsbury, M.D. Pediatrics · Portland, OR
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Cincinnati Children's Hospital Medical Center, OH $24,050
- Childrens Research Institute $19,930
- Legacy Emanuel Medical Center, OR $11,455
- Wake Forest University $3,274
- New York Medical College $270
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.